產(chǎn)品屬性：
產(chǎn)品名稱 | Autocamtide-2-related inhibitory peptide |
規(guī)格 | 1mg、5mg、10mg |
貨號 | EY-01Y11952 |
Cas No.: 167114-91-2
化學名: (2S,3Z,5S,6Z,8S,9Z,11S,12Z,14S,15Z,17S)-17-((Z)-((2S,3Z,5S,6Z,8S,9Z,11S,12Z,14S,15Z,17S,18Z,20S,21Z)-17,20-bis(4-aminobutyl)-5,8-bis(3-guanidinopropyl)-1,4,7,10,13,16,19,22-octahydroxy-2-(3-hydroxy-3-iminopropyl)-11-isobutyl-14-m
分子量: 1822.14
溶解度: DMF: 30 mg/ml,DMSO: 30 mg/ml,PBS (pH 7.2): 10 mg/ml
儲存條件: Desiccate at -20°C
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
產(chǎn)品描述：
IC50: 40 nM for CaM-kinase II [1].Synthetic peptide AIP (autocamtide-2-related inhibitory peptide) is a nonphosphorylatable analog of autocamtide-2, which was identified to be a highly specific and potent inhibitor of calmodulin-dependent protein kinase II (CaM-kinase II, CaMKII). CaMKII is a serine/threonine-specific protein kinase, which is modulated by the Ca2+/calmodulin.In vitro: AIP (1 mM) completely inhibited CaMKII activity, but did not affect cAMP-dependent protein kinase, calmodulin-dependent protein kinase IV and protein kinase C,. The inhibition was noncompetitive, and the action was caused by binding to the autophosphorylation site, which is distinc from that for the exogenous substrate. The IC50 for the autophosphorylation of CaM II is 100 nM [1].In vivo: Mice treated with AIP by transgenic expression of AIP, were protected from fructose-rich diet-induced arrhythmogenesis, spontaneous contractions and spontaneous Ca2+ release events [2]. Intra-nucleus accumbens (NAc) injection of AIP could dose-dependently increase the HWL (hindpaw withdrawal latency) to noxious thermal and mechanical stimulation in rats with mononeuropathy [3].Clinical trial: So far, no clinical study has been conducted.
特別提醒公司產(chǎn)品僅供科研使用
